The short version of receptor agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-01. Anything still debated is marked as such rather than presented as settled.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
== Legume-based == Burmese tofu – made from water, chickpea flour and turmeric Falafel – a traditional Middle Eastern bean fritter, believed to have been created by ancient Copts as a meat substitute during Lent Härkis – a brand of processed ground fava beans
== Treatment == Treatment for diabulimia has two goals: stabilizing diabetes by increasing insulin intake and addressing the underlying eating disorder. The standard approach for the treatment of two complex conditions involves a multidisciplinary team of professionals. This team may include an endocrinologist, a psychiatrist, a psychologist, and a dietician. There are several treatment centers in the United States that have programs specifically designed for the co-morbidity of diabetes and eating disorders. There is one non-profit in the U.S. devoted to the education, support, and advocacy for people with diabetes and eating disorders. DBH runs a 24 hour toll-free crisis hotline +1.425.985.364 open 365 days a year.
The first 16 months of the MD program, the preclerkship phase, consists of fundamental scientific and medical coursework. Multi-semester courses include bioethics and service learning. This is followed by a 12-month clinical phase that includes clerkships and preparation for and completion of the United States Medical Licensing Examination (USMLE) Step 1. Clerkships are followed by completion of the USMLE Step 2 exam. The final 18 months of medical school include clinical electives, increased clinical duties, and a research capstone project. In addition to Jacobi and Montefiore hospitals, medical students can train in medical facilities such as the VA Bronx Healthcare System and Bronx Psychiatric Center. Students may also volunteer at the Einstein Community Health Outreach (ECHO) Free Clinic, which provides care to those without health insurance. Founded in 1999, ECHO was the first such clinic in New York City and one of the first in the United States.
==== Electrochemical fluorination ==== Electrochemical fluorination (ECF) (also known as the Simons' process) involves electrolysis of a substrate dissolved in hydrogen fluoride. As fluorine is itself manufactured by the electrolysis of hydrogen fluoride, ECF is a rather more direct route to fluorocarbons. The process proceeds at low voltage (5 – 6 V) so that free fluorine is not liberated. The choice of substrate is restricted as ideally it should be soluble in hydrogen fluoride. Ethers and tertiary amines are typically employed. To make perfluorohexane, trihexylamine is used, for example:
Sources: en.wikipedia.org
By the early 1980s, the USSR had built up a military arsenal and army surpassing that of the United States. Soon after the Soviet invasion of Afghanistan, President Carter began massively building up the United States military. This buildup was accelerated by the Reagan administration, which increased the military spending from 5.3 percent of GNP in 1981 to 6.5 percent in 1986, the largest peacetime defense buildup in United States history. The American-Soviet tensions present during 1983 was defined by some as the start of "Cold War II". While in retrospective this phase of the Cold War was generally defined as a "war of words", the Soviet's "peace offensive" was largely rejected by the West. Tensions continued to intensify as Reagan revived the B-1 Lancer program, which had been canceled by the Carter administration, produced LGM-118 Peacekeeper missiles, installed US cruise missiles in Europe, and announced the experimental Strategic Defense Initiative, dubbed "Star Wars" by the media, a defense program to shoot down missiles in mid-flight. The Soviets deployed RSD-10 Pioneer ballistic missiles targeting Western Europe, and NATO decided, under the impetus of the Carter presidency, to deploy MGM-31 Pershing and cruise missiles in Europe, primarily West Germany. This deployment placed missiles just 10 minutes' striking distance from Moscow.
=== Remotely controlled ovens === Embedded Web Technology (EWT) software—originally developed by NASA for use by astronauts operating experiments on the International Space Station—lets a user monitor and/or control a device remotely over the Internet. NASA supplied this technology and guidance to TMIO LLC, which developed remote control and monitoring of a new intelligent oven product named "Connect Io." With combined cooling and heating capabilities, Connect Io refrigerates food until a customized pre-programmable cooking cycle begins. The menu allows the user to simply enter the dinner time, and the oven automatically switches from refrigeration to the cooking cycle, so that the meal will be ready as the family arrives home for dinner.
An immigration stamp is an inked impression in a passport or other travel document, typically made by a rubber stamp upon entering or exiting a territory. Depending on the jurisdiction, a stamp can serve different purposes. For example, in the United Kingdom, an immigration stamp in a passport includes the formal leave to enter granted to a person subject to entry control. In other countries, a stamp activates or acknowledges the continuing leave conferred in the passport bearer's entry clearance. Under the Schengen system, a foreign passport is stamped with a date stamp which does not indicate any duration of stay. This means the person is deemed to have permission to remain for either 3 months or the period shown on their visa, if specified otherwise. Member states of the European Union are not permitted to place a stamp in the passport of a person who is not subject to immigration control. Stamping is prohibited because it imposes a control to which the person is not subject. Passport stamps may occasionally take the form of sticker stamps, such as entry stamps from Japan. Depending on nationality, a visitor may not receive a stamp at all (unless specifically requested), such as an EU or EFTA citizen travelling to an EU or EFTA country, Albania, or North Macedonia. Most countries issue exit stamps in addition to entry stamps. A few countries issue only entry stamps, including Canada, El Salvador, Ireland, Mexico, New Zealand, Singapore, United Kingdom and the United States of America.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.